7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Cancer Care

Can a Second Opinion Change a Pancreatic Cancer Plan? When Surgical Review Is Requested

23 min read
Can a Second Opinion Change a Pancreatic Cancer Plan? When Surgical Review Is Requested

Key Takeaways

  • The question a pancreatic cancer surgical review answers is not 'is there a tumor' but 'how much of a major blood vessel does it touch', because that contact decides whether an operation is realistic.
  • A true second opinion re-reads the actual CT or MRI images and ideally takes the case to a multidisciplinary tumor board; reviewing only the written report is not enough.
  • The most common outcome of a review is agreement with the first plan, and the next most common is a change in sequence, such as chemotherapy before surgery rather than after.
  • Tumors labelled borderline resectable or locally advanced are routinely re-evaluated for surgery after initial chemotherapy, so 'not operable now' is often not a permanent verdict.
  • The liver is the most frequent site of spread, and finding deposits there usually shifts the plan from surgery toward systemic treatment, which is why reviewers check it first.
  • A review should run alongside treatment, not instead of it; ask your current team for a decision deadline so the surgical question is settled without delaying care.
Quick Answer

A second opinion can change a pancreatic cancer plan, though it more often confirms one. A surgical review re-reads the scans to judge whether the tumor can be removed, whether chemotherapy should come first, and whether the person is fit for a major operation. Any change is agreed with the treating team, not made by the reviewer alone.

The folder sits on the kitchen table for three days before anyone opens it again. Inside are the CT report, a letter that uses the phrase ‘locally advanced’, and a treatment plan that was explained in a room where nobody could quite keep up. One sentence from that appointment keeps replaying: ‘We don’t think this is operable right now.’ The word ‘right now’ is doing a lot of work, and the family wants to know how much.

This is the moment many people ask about a pancreatic cancer second opinion. Not because they distrust the first team, but because pancreatic tumors sit in one of the most crowded neighborhoods in the body, and judging whether a tumor can be lifted out safely is a skill that benefits from more than one set of eyes.

What follows explains what a surgical review involves, who is usually offered one, what it can and cannot change, and how to request it without losing time that matters.

What a pancreatic cancer second opinion actually involves

A second opinion is a structured review of your case by a clinician or team not involved in the first assessment. For pancreatic cancer, the review usually has two halves. One is medical: is the diagnosis secure, is the stage correct, is the proposed sequence of chemotherapy, radiation or surgery consistent with current guidelines? The other is surgical: can this tumor be removed, and is this person well enough to recover from the operation?

In practice the reviewing team asks for your original images, not just the written reports. Radiologists re-read the CT or MRI slice by slice, looking at how the tumor relates to the nearby blood vessels. Pathologists may re-examine the biopsy slides. A surgeon then forms a view and brings it to a tumor board, the multidisciplinary meeting where surgeons, oncologists, radiologists and others discuss cases together. The National Cancer Institute’s treatment summary describes this team-based approach as the standard way pancreatic cancer decisions are made.

What you receive at the end is an opinion, written or spoken, that either agrees with the first plan, suggests a modification, or proposes a different path. It is not a new prescription. Your treating team, whichever team you choose to proceed with, remains responsible for the decisions. The reviewers are adding information, and sometimes a different judgment call, to a situation that genuinely allows for more than one reasonable answer.

Many people find the process reassuring even when nothing changes. Hearing a second expert say ‘I would do the same’ turns a frightening plan into a shared one.

Why pancreatic cancer plans get revisited more than most

The pancreas is a soft, finger-shaped gland tucked behind the stomach, and it sits against vessels the body cannot do without. The superior mesenteric artery and vein feed and drain the intestine. The portal vein carries blood to the liver. The celiac axis supplies the stomach, liver and spleen. A tumor a few centimeters across can brush, wrap around or grow into these structures, and the difference between brushing and wrapping can decide whether surgery is possible.

Doctor consulting patient about healthy salad diet: Why pancreatic cancer plans get revisited more than most

Scans show this relationship in shades of gray that experienced readers interpret differently. One radiologist may describe contact with a vein as ‘abutment’, another as ‘encasement’. Those words map onto different treatment categories. That is not sloppiness; it reflects a judgment made on imaging that has real limits, as the Mayo Clinic notes in its description of how pancreatic cancer is staged.

Two other features make this cancer unusual. The first is that it is often found late. MedlinePlus explains that early pancreatic cancer rarely causes symptoms, so many people are diagnosed once the tumor has already involved nearby structures or spread. The second is that the main operation, the Whipple procedure, which removes the head of the pancreas, part of the small intestine, the gallbladder and the bile duct, is among the larger abdominal surgeries performed. According to the Mayo Clinic the operation can take 4 to 12 hours and is followed by a hospital stay of roughly a week or more.

Combine a hard-to-read tumor with a demanding operation and you have a disease where reasonable experts can disagree. That is the honest reason second opinions are common here, and why guideline bodies encourage multidisciplinary review rather than a single clinician’s call.

Who is usually offered a second opinion pancreatic cancer surgery review, and who is asked to wait

A surgical review is most useful when the question of operability is genuinely open. Several situations tend to prompt one.

  • The tumor has been labelled ‘borderline resectable’ or ‘locally advanced’, categories where surgeons may differ on whether an operation is realistic, now or after chemotherapy.
  • The first team recommended surgery, and the person wants confirmation before committing to a long recovery.
  • The first team said surgery was not an option and did not explain which finding ruled it out.
  • The tumor involves a vein, and the question is whether a surgeon comfortable with vein reconstruction would see it differently.
  • Chemotherapy has already shrunk the tumor, and the original ‘not operable’ label may no longer apply.

People are sometimes asked to pause a surgical review, or told it is unlikely to help, in a few circumstances. When imaging clearly shows spread to the liver, lungs or the lining of the abdomen, the question of removing the primary tumor becomes secondary, because the disease is already systemic; the NCI treatment summary describes chemotherapy rather than surgery as the usual approach at that stage. When someone is too unwell to tolerate a major operation, a surgeon’s view will not change that reality, though a review of fitness itself can be valuable. And when a person is already mid-way through a chemotherapy cycle, teams usually prefer to complete that block and restage before asking a surgeon to re-read the scans.

None of this means a review is forbidden in those situations. It means the yield is lower, and the treating team may suggest focusing energy elsewhere first. That advice, like every decision in this process, belongs to the team looking after you.

What the surgeon is really looking at when they re-read your scans

A surgical second opinion rests on three questions, and it helps to know them because they shape what the reviewer asks for.

Doctor reviewing CT scan with male patient at desk: What the surgeon is really looking at when they re-read your scans

First, where exactly is the tumor and what does it touch? The reviewer wants a pancreas-protocol CT, a scan timed so that arteries and veins light up at the right moments. On it, the surgeon traces each major vessel and measures how many degrees of its circumference the tumor contacts. The Mayo Clinic’s overview of pancreatic cancer diagnosis describes CT and MRI as the main tools for this, sometimes supported by endoscopic ultrasound, an ultrasound probe passed through the stomach to look at the pancreas from inside.

Second, is there disease elsewhere? A tumor that could be removed locally is not usually removed if the liver already contains deposits. Reviewers look at the liver, the lungs and the lining of the abdomen with the same care they give the pancreas. Blood tests such as CA 19-9, a protein that many pancreatic cancers release, add context, though MedlinePlus notes it is not reliable on its own.

Third, can this person recover from the operation? Age alone is not the deciding factor; function is. Heart and lung reserve, nutrition, recent weight loss, diabetes control and the ability to walk and climb stairs all feed into the judgment. Some reviewers request formal fitness testing. Jaundice, the yellowing caused by a blocked bile duct, may need a stent placed before surgery can be considered.

Only after all three questions are answered does the surgeon give a view. A review that skips any of them is incomplete, and it is fair to ask whether each was addressed.

Resectable, borderline resectable pancreatic cancer and beyond: the categories that decide the plan

Most disagreements in pancreatic cancer come down to which of four categories a tumor belongs to. The National Cancer Institute’s treatment summary organizes care around them, and a second opinion often moves a case from one column to another.

Category What it means on imaging Usual first step Where second opinions most often differ
Resectable Tumor is clear of major arteries; little or no vein contact Surgery, often followed by chemotherapy; sometimes chemotherapy first Whether to give chemotherapy before surgery
Borderline resectable Tumor touches or partly surrounds a vein or artery but is not fully encased Chemotherapy, sometimes with radiation, then re-evaluation for surgery Whether the vessel contact is reconstructable
Locally advanced (unresectable) Tumor encases a major artery or blocks a vein without a reconstruction option Chemotherapy, sometimes radiation; surgery only if the tumor responds Whether ‘encasement’ was over-called
Metastatic Deposits in the liver, lungs, abdominal lining or distant nodes Chemotherapy; surgery not usually part of the plan Rarely on surgery; more often on drug choice or trials

The middle two rows are where surgical review earns its keep. The line between ‘borderline’ and ‘locally advanced’ rests on degrees of vessel contact and on what a particular surgeon is prepared to reconstruct. A plan that reads ‘not operable’ may, on review, become ‘not operable yet, let’s treat and look again’, which is a materially different plan with a different emotional weight.

The table is a simplification. Tumors in the body or tail of the pancreas, rarer tumor types such as neuroendocrine tumors, and individual fitness all shift the calculus. Treat it as a map of the conversation, not a verdict.

What a second opinion can change, and what it usually confirms

People often imagine a second opinion as a binary: either the first team was right or they were wrong. The real outcomes are more textured, and most are modest adjustments rather than reversals.

The most common result is agreement. The reviewing surgeon looks at the same vessels, reaches the same category, and endorses the same sequence. That is not a wasted exercise; it removes the nagging ‘what if’ that otherwise follows a person through months of treatment.

The next most common result is a change in order rather than substance. Both teams agree surgery is possible, but the reviewer suggests chemotherapy first, a strategy known as neoadjuvant therapy, meaning treatment given before an operation to shrink the tumor and treat cells that may already have escaped. The NHS describes chemotherapy before surgery as one of the standard approaches, and reasonable surgeons weigh it differently.

Less often, the category itself changes. A tumor read as encasing an artery is re-read as abutting it, and a person who was told surgery was off the table is told it may be possible after a response to chemotherapy. The reverse also happens: a review finds a small liver deposit the first read missed, and a planned operation is cancelled in favor of systemic treatment. That is painful news, but it spares someone a major operation that would not have helped.

Finally, a review may open doors the first plan did not mention: a clinical trial, a referral for genetic testing, or a different surgical technique. The reviewer raises these; your treating team decides whether and how to pursue them.

Does getting a second opinion delay treatment?

This is the fear that stops many people from asking, and it deserves a straight answer: a well-organized review rarely delays treatment meaningfully, and it should never be allowed to.

Pancreatic cancer is time-sensitive. The NHS treatment guidance notes that it is often diagnosed at an advanced stage, which is exactly why clinicians work to a short pathway from diagnosis to first treatment. A second opinion fits inside that pathway when it runs in parallel with the steps already underway. Staging scans, biopsy, bile duct stenting if needed, and fitness assessment are required whatever happens next; a reviewing team uses those same results rather than repeating them.

The practical bottleneck is usually administrative: getting images transferred, slides sent, and an appointment booked. Ask your first team to help. Most are comfortable with second opinions and will say so if asked directly. A good question is: ‘If I seek a review, what is the latest date you would want a decision by, so nothing is held up?’ That turns an awkward request into a scheduling problem the team can solve.

In one situation a review should not postpone anything. If the plan is chemotherapy, and both the first team and your own instincts agree it is needed, chemotherapy can usually start while a surgical review proceeds. Surgery for borderline and locally advanced tumors is typically considered after several cycles anyway, so the surgeon’s view is needed at the point of restaging, not before the first infusion.

If a review would mean weeks with no treatment at all, raise that explicitly with both teams and ask which carries the greater risk.

What the following days and weeks usually look like

The sequence varies by health system, but the shape is familiar. The timeframes here are typical ranges and depend on local arrangements rather than on any promise.

The first few days are about paperwork and transfer. You or your team request your imaging on disc or via a secure link, the radiology report, the pathology report, blood results and any clinic letters. Reviewing teams almost always want the images themselves, because the surgical question lives in the pictures, not the prose.

The next step is the review itself. In many centers the case is discussed at the weekly multidisciplinary meeting, so there is often a wait of up to a week or so for the next scheduled board. Some teams offer a virtual review in which the surgeon and radiologist examine your scans without you attending in person, followed by a video or phone consultation.

Then comes the conversation. Expect the reviewing clinician to explain which category they place the tumor in, why, and what they would propose. Ask for this in writing, because a letter can be read calmly at home and shared with your first team.

In the weeks after, the two teams may talk to each other directly, which is the ideal outcome. If chemotherapy has started, a restaging scan after several cycles becomes the natural point to revisit the surgical question. The NCI summary notes that patients with borderline and locally advanced disease are re-evaluated for surgery after initial treatment; that re-evaluation is where the second opinion’s value often becomes concrete.

If at any point you feel the review is drifting without a date attached, ask for one.

When to get a second opinion for cancer: the signals that matter most

Not every diagnosis needs a second opinion, and some people find the extra appointments more stressful than reassuring. Certain signals, though, make the case strong enough that most clinicians would support asking.

The plan hinges on a word you were not shown the evidence for. ‘Unresectable’ and ‘borderline’ are judgments; if nobody has walked you through the scan showing which vessel is involved and how, a second set of eyes is reasonable.

The recommendation is for a major operation, and recovery will take months. The Mayo Clinic describes the Whipple procedure as a complex operation with a meaningful risk of complications. Before committing to that, wanting confirmation is not disloyalty.

The first team has limited experience with this specific situation. Pancreatic surgery is a specialized field, and a surgeon who performs the operation only occasionally may reasonably prefer to refer complex vessel-involved tumors elsewhere. Asking ‘how often do you see tumors like mine?’ is fair.

Your diagnosis has an unusual feature: a rare tumor type, a tumor found incidentally, a cyst that has changed, or a strong family history that raises questions about genetic testing.

Finally, and simply: you are not at peace with the plan. Doubt that follows you home will follow you into treatment. A review that produces agreement converts doubt into resolve, which is worth having before a long course of therapy.

What a second opinion is not for is shopping for the answer you want. If two independent teams reach the same conclusion, a third is unlikely to help and may cost time you need.

How a pancreatic cancer multidisciplinary team reaches a decision

Behind every surgical opinion sits a meeting most patients never see. The multidisciplinary team, often called a tumor board, is where a pancreatic cancer plan is actually made, and understanding it explains why second opinions are structured the way they are.

A typical board includes a pancreatic surgeon, a medical oncologist who prescribes chemotherapy, a radiation oncologist, a radiologist, a pathologist, a gastroenterologist who manages stents and biopsies, and a specialist nurse or coordinator. Cases are presented one at a time. The radiologist walks the room through the scan, pointing out vessel contact. The pathologist confirms the tumor type. The surgeon states whether and when an operation is realistic. The oncologists outline systemic options. A consensus is recorded and communicated to the patient.

The NCI treatment summary and the NHS both describe this team model as standard for pancreatic cancer. Its strength is that no single clinician’s blind spot determines the outcome. Its limit is that boards vary in their appetite for aggressive surgery and in their access to vein reconstruction and advanced radiation techniques. Two excellent boards can land on different plans for the same scan.

This is why a meaningful second opinion is really a second board, not a second doctor. When you request one, it is reasonable to ask whether your case will be discussed at a multidisciplinary meeting and whether a radiologist will re-read the images rather than rely on the original report.

Ask, too, whether the two boards can communicate. A phone call between surgeons often resolves what months of letters cannot, and it keeps the decision where it belongs, with the team treating you.

Can pancreatic cancer spread to the liver, and how does that change surgical review?

Yes. The liver is the most common site for pancreatic cancer to spread, because blood from the pancreas drains through the portal vein straight into it. The lungs and the peritoneum, the thin lining of the abdominal cavity, are the other frequent sites, as MedlinePlus and the NCI describe.

For a surgical review, this is the first thing the reviewing surgeon checks, and it explains why a seemingly removable pancreatic tumor is sometimes not operated on. Removing the primary tumor does not treat deposits that are already elsewhere, and the operation itself carries real risk and a recovery measured in months. When metastases are present, guidelines steer toward chemotherapy as the main treatment, with surgery reserved for rare circumstances discussed case by case.

The review also probes uncertainty. Small spots in the liver are common and most are benign cysts or blood-vessel tangles. A radiologist re-reading your scan may call for an MRI of the liver, which sees these lesions more clearly than CT, before anyone labels them as cancer. Occasionally a surgeon proposes a laparoscopy, a short keyhole look inside the abdomen, to check the liver surface and peritoneum directly before committing to a larger operation; the NCI summary lists this among the staging tools.

What people sometimes ask next is whether the liver deposits could be removed too. In pancreatic cancer this is not standard, and the evidence base is limited; the NCI summary does not describe it as routine care. A reviewing team may mention clinical trials exploring this question. If they do, it is a research option to discuss, not a recommendation.

Survival rates by age, and why a single number cannot guide your plan

One of the most searched questions about this cancer is a statistic, and people are entitled to the answer. Published survival figures exist, and your treating team can share the ones that apply to your stage and situation. This article does not reproduce them, for a reason worth explaining.

Survival statistics are averages across thousands of people diagnosed years ago, mixing every stage, every tumor type, every level of fitness and every treatment era. The NCI treatment summary is careful to describe prognosis in terms of stage, resectability and general health rather than as one figure. A person with a small resectable tumor and good fitness and a person with liver metastases and poor appetite both contribute to the same headline number, yet their situations are nothing alike.

Age illustrates the problem. Older people as a group have more coexisting illness and are less often offered surgery, so age-stratified figures partly reflect treatment patterns rather than biology. A fit person in their late seventies may be a better surgical candidate than a frail person two decades younger. Surgeons assess function, not birthdays.

What a second opinion can offer instead of a number is a sharper description of your own category, and a clearer account of what the proposed plan is trying to achieve. For some, the aim is to remove the tumor completely and reduce the chance it returns. For others, the aim is to control the disease, protect quality of life and extend time well. Both are legitimate goals, and a review that clarifies which applies is more useful than any percentage.

If you want figures, ask your team for the ones that match your stage, and ask what assumptions sit behind them.

What people often get wrong about pancreatic cancer second opinions

A second opinion will offend my doctor. Most oncologists and surgeons expect the request and many raise it themselves. A clinician who reacts badly is telling you something about their comfort with scrutiny, not about the appropriateness of your question.

‘Not operable’ means ‘nothing can be done’. These are different statements. Many tumors labelled unresectable are treated with chemotherapy and sometimes radiation, and a proportion become candidates for surgery after a response; the NCI summary describes this re-evaluation explicitly. Others are controlled for extended periods without surgery.

A more aggressive surgeon is a better surgeon. Willingness to operate is not the same as wisdom about when to. A surgeon who declines a technically possible operation because the likely benefit is small is exercising judgment, not timidity. The point of a review is to find the right plan, not the boldest one.

The second opinion overrides the first. It does not. It is advice. Your treating team incorporates it, or explains why they disagree, and you decide with them.

Chemotherapy before surgery means the cancer is worse. In pancreatic cancer, chemotherapy first is increasingly used even for tumors that could be removed straight away, for reasons the NHS outlines: to shrink the tumor and treat cells that may have spread. It is a strategy, not a downgrade.

A scan report is the final word. Reports are summaries written by one reader. The images are the evidence, and a review that only reads the report is not a true second opinion.

Finally, more opinions are better. Two concordant reviews are usually enough. A third rarely adds signal and often adds weeks.

Questions to ask your care team before and after a surgical review

The quality of a second opinion depends partly on the questions you bring. These are the ones that tend to produce useful answers, grouped by when to ask them.

Before requesting the review, ask your current team: Which category do you place my tumor in, and which finding on the scan drives that? Would chemotherapy first change the surgical picture? Is there a date by which you need a decision so treatment is not delayed? Can you help transfer my images and slides?

When choosing where to be reviewed, ask: Will a radiologist re-read my actual images? Will my case go to a multidisciplinary meeting? Does your team perform vein reconstruction, and how does that affect what you would call borderline? Will you write to my current team?

During the review consultation, ask: Do you agree with the stage and the category? If not, what specifically do you see differently? What would your plan be, in what order, and what is each step trying to achieve? What are the risks of the operation you are describing, and what does recovery usually involve? What would make you change your mind at restaging? Are there clinical trials relevant to my situation?

Afterwards, ask your treating team: Having seen the second opinion, what is our plan now? If you disagree with the reviewer, why? Who is coordinating the next step, and when will I hear?

Bring someone with you, or ask to record the conversation. Write down the answers. A review is only as good as what you are able to carry out of the room and back to the people treating you.

When to call your doctor

The weeks around a second opinion can feel like a holding pattern, but pancreatic cancer does not pause, and some developments need same-day attention regardless of where the review stands. Contact your treating team promptly, or seek emergency care, if any of the following occur. These are drawn from the Mayo Clinic and MedlinePlus descriptions of pancreatic cancer and its complications.

  • Yellowing of the skin or whites of the eyes, dark urine, or pale stools, which can signal a blocked bile duct that may need a stent before any treatment can proceed.
  • Fever, chills or shaking, especially with jaundice or an existing stent, which can indicate infection in the bile duct and needs urgent assessment.
  • Persistent vomiting or inability to keep fluids down, which may mean the tumor is blocking the outlet of the stomach.
  • Severe or rapidly worsening abdominal or back pain that your current medicines do not control.
  • Black or bloody stools, vomiting blood, or sudden faintness, which can indicate bleeding.
  • Sudden swelling, pain or warmth in one leg, or unexplained breathlessness or chest pain, because pancreatic cancer raises the risk of blood clots, as the Mayo Clinic notes.
  • Rapid weight loss, new confusion, or very high or very low blood sugar readings in someone with diabetes, since the pancreas regulates insulin.

If you are between teams, call the one that most recently saw you; do not wait for the review to conclude. Mention that a second opinion is in progress so both teams can be kept informed. And if something feels seriously wrong and you cannot reach anyone, go to an emergency department. Nothing in a review process is worth more than being seen quickly when it matters.

Frequently asked questions

Can a pancreatic cancer second opinion really change the treatment plan?

Yes, though confirmation is the most common result. Reviews change plans most often by altering the order of treatment, for example recommending chemotherapy before surgery, or by moving a tumor between categories such as borderline and locally advanced after re-reading the scans. Any change is discussed with your treating team, which keeps responsibility for the final decision.

When should I get a second opinion for pancreatic cancer surgery?

The strongest reasons are a tumor labelled borderline or locally advanced, a recommendation for a major operation you want confirmed, a plan that was not explained with reference to the scan, or a first team with limited experience of vessel-involved tumors. Ask early, ideally while staging is being completed, so the review runs alongside rather than ahead of treatment.

What is borderline resectable pancreatic cancer?

It is a tumor that touches or partly surrounds a major vein or artery near the pancreas without fully encasing it. The usual first step is chemotherapy, sometimes with radiation, followed by repeat scans to judge whether surgery has become possible. Surgeons differ on where the borderline sits, which is why this category is where second opinions most often add value.

Will a second opinion delay my pancreatic cancer treatment?

Not if it is organized well. Staging scans, biopsy and fitness checks are needed whatever happens next, and a reviewing team uses those results rather than repeating them. Chemotherapy can usually begin while a surgical review proceeds. Ask your current team for the latest date by which they need a decision so nothing is held up.

Can pancreatic cancer metastasize to the liver?

Yes, and the liver is the most common site, because blood from the pancreas drains directly into it through the portal vein. Confirmed liver deposits usually shift the plan toward chemotherapy rather than surgery. Small liver spots are often benign, so a reviewing radiologist may request an MRI before labelling anything as cancer.

Can pancreatic cancer be treated with the aim of removing it completely?

For tumors that are resectable, or that become so after chemotherapy, surgery aims to remove all visible disease and is usually combined with chemotherapy to treat cells that may have spread. Whether that aim is realistic depends on stage, vessel involvement and fitness, which is exactly what a surgical review assesses. Your team can explain which goal applies to you.

What do survival rates for pancreatic cancer by age actually tell me?

Less than they seem to. Published figures average across all stages, tumor types and treatment eras, and age-based numbers partly reflect that older people are offered surgery less often rather than differences in biology. Surgeons judge fitness, not birthdays. Ask your treating team for figures that match your specific stage and the assumptions behind them.

Does a pancreatic cancer multidisciplinary team meeting happen as part of a second opinion?

It should. A meaningful review takes your images to a tumor board where a surgeon, oncologists, a radiologist and a pathologist discuss the case together, rather than relying on one clinician reading the original report. When arranging a review, ask whether your case will be discussed at such a meeting and whether the images will be re-read.

What records do I need to send for a surgical second opinion?

The actual imaging files for your CT or MRI, not just the reports; the pathology report and, if requested, the biopsy slides; blood results including CA 19-9; and recent clinic letters describing the proposed plan. Your current team can help transfer these. Reviewers consistently say the images themselves are the single most important item.

What if the two opinions disagree about my pancreatic cancer plan?

Ask both teams to speak to each other directly, which often resolves differences faster than letters. Then ask each to explain which specific finding drives their view and what would change their mind at restaging. Disagreement usually reflects genuine uncertainty about vessel contact or fitness, not error. You and your treating team make the final choice together.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 18, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.